BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Clinical Trials

Shanghai ArkBio Completes Phase III Trial of AK0901 for Pediatric ADHD in China

Shanghai Ark Biopharmaceutical Co., Ltd. announced the successful completion of the Phase III clinical study of AK0901, a novel drug for the treatment of a...

March 25, 2025 | News

Ractigen Reports Promising Phase I Data for First-in-Class saRNA Therapy RAG-01 in Bladder Cancer

Ractigen Therapeutics, a clinical-stage biopharmaceutical company pioneering small activating RNA (saRNA) therapeutics, announced the presentation of...

March 25, 2025 | News

Sungen Biomedical Secures FDA Fast Track Designation for AMI Drug Candidate SGC001

Sungen Biomedical—an innovative biopharmaceutical company incubated by Beijing Hotgen Biotech Co., Ltd. (SH.688068)—received Fast Track Designa...

March 25, 2025 | News

Akeso Showcases Positive Phase III Safety Run-In Data for Cadonilimab at SGO 2025 in Locally Advanced Cervical Cancer

Akeso Inc. (9926.HK) presented promising phase III safety run-in results from the COMPASSION-18/AK104-305 study, at the 2025 Annual Meeting of the Society ...

March 24, 2025 | Report

Syneron Bio Enters $3.5B Strategic Collaboration with AstraZeneca to Develop Novel Macrocyclic Peptide Therapies

Syneron Bio, a cutting-edge oral macrocyclic peptide drug biotech company, announced today a strategic collaboration with the global biopharmaceutical lead...

March 24, 2025 | News

Dizal to Present New Findings on Golidocitinib-PD-1 Combo and Sunvozertinib-Anlotinib Therapy at ELCC 2025

Dizal (SSE: 688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced ...

March 21, 2025 | News

TiumBio and Hansoh Pharma Gain Clinical Trial Approval in China for Merigolix in ART-Related Controlled Ovarian Stimulation

Clinical Trial Approval of merigolix (TU2670, HS-10518) for the inhibition of premature LH (luteinizing hormone) surges in women undergoing COS (con...

March 21, 2025 | News

Teva Hong Kong Partners with Kerry Pharma to Enhance Medicine Distribution Across Hong Kong, Macau, and the Greater Bay Area

Teva Hong Kong ("Teva"), has announced a strategic partnership with Kerry Pharma, the subsidiary of Kerry Logistics Network Ltd ("KLN"). Leveraging Ke...

March 17, 2025 | News

Exicure Secures Australian Patent for Dual-Target Cancer Therapy Approach

Exicure, Inc. announced that the Australian Patent Office has issued Patent No. 2018388302, titled "GPCR Heteromer Inhibitors and Uses Thereof." ...

March 14, 2025 | News

BioCity Biopharmaceutics and MSD Partner to Evaluate BC3195-KEYTRUDA® Combo in Global Phase 1/2 Trial

BioCity Biopharmaceutics Co., Ltd., a clinical-stage biopharmaceutical company, announced that it has entered into a clinical trial collaboration agr...

March 14, 2025 | News

GC Cell Begins Phase 1 Clinical Trial for CD5 CAR-NK Therapy GCC2005 in T-Cell Lymphomas

GC Cell , under the leadership of CEO Sungyong Won, announced today the initiation of its domestic Phase 1 clinical trial for GCC2005 (AB‑205), a no...

March 13, 2025 | News

Ascletis’ ASC47 Shows Promise as a Long-Acting, Muscle-Preserving Obesity Treatment in Phase Ib Study

ASC47, an adipose-targeted muscle-preserving weight loss drug candidate for the treatment of obesity, demonstrated a half-life of up to 26 days and ...

March 12, 2025 | News

Zhejiang Doer Biologics Completes Phase 2 Enrollment for First-in-Class Tri-Agonist DR10624 in Severe Hypertriglyceridemia

Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and...

March 11, 2025 | News

SPRIM Global Investments and OneIM Launch $300M Joint Venture to Accelerate Clinical Trial Financing

SPRIM Global Investments ("SGI"), a global investment firm specializing in clinical-stage life sciences and pharma services based in Singapore, and On...

March 11, 2025 | News

Stay Connected